Embolization Clinical Trials

24 recruitingLast updated: May 21, 2026

There are 24 actively recruiting embolization clinical trials across 11 countries. Studies span Not Applicable, Phase 2, Phase 3. Top locations include Seoul, South Korea, Chengdu, Sichuan, China, Ürümqi, Xinjiang, China. Updated daily from ClinicalTrials.gov.


Embolization Trials at a Glance

24 actively recruiting trials for embolization are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Not Applicable with 12 trials, with the heaviest enrollment activity in Seoul, Chengdu, and Ürümqi. Lead sponsors running embolization studies include Seoul National University Hospital, Sun Yat-sen University, and Xinjiang Medical University.

Browse embolization trials by phase

About Embolization Clinical Trials

Looking for clinical trials for Embolization? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Embolization trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Embolization clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Not Applicable

Scout Dose of Resin Microspheres

Hepatocellular Carcinoma (HCC)Intrahepatic Cholangiocarcinoma (Icc)Liver Metastasis+1 more
Seoul National University Hospital30 enrolled1 locationNCT07476651
Recruiting
Phase 3

TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular CarcinomaApatinibCamrelizumab+1 more
Guohui Xu101 enrolled1 locationNCT06485466
Recruiting
Not Applicable

NOn-inVAsive Blood Pressure Monitoring in Intracranial Aneurysm Embolization

Hemodynamic InstabilityIntracranial AneurysmsCerebral Aneurysms+2 more
Korea University Anam Hospital50 enrolled1 locationNCT07246148
Recruiting
Not Applicable

qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver

RadioembolizationTransarterial ChemoembolizationTransarterial Embolism
University of Wisconsin, Madison20 enrolled1 locationNCT06971991
Recruiting

A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

HCC - Hepatocellular CarcinomaCTTACE(Transcatheter Arterial Chemoembolization)
Zhongda Hospital250 enrolled1 locationNCT07351669
Recruiting
Phase 3

Adjuvant TACE in HCC With High-risk Recurrence Factors

Hepatocellular CarcinomaAdjuvantTransarterial Chemoembolization
Guangxi Medical University442 enrolled1 locationNCT07417397
Recruiting
Not Applicable

Embolization Treatment of Chronic Refractory Shoulder Tendinopathy

Rotator cuff tendinitisShoulder PainRotator Cuff Tendinosis+3 more
Brigham and Women's Hospital41 enrolled1 locationNCT06095050
Recruiting

Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B Cell LymphomaTransarterial ChemoembolizationRelapsed and Refractory
Ting YANG10 enrolled1 locationNCT07198230
Recruiting
Not Applicable

Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization

Hepatocellular CarcinomaTransarterial Chemoembolization
Taichung Tzu Chi Hospital60 enrolled1 locationNCT07178093
Recruiting
Not Applicable

Glue Embolization vs Conservative Treatment for Pelvic Congestion Syndrome

Glue EmbolizationPelvic Congestion Syndrome
Tanta University40 enrolled1 locationNCT06560294
Recruiting
Not Applicable

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

Hepatocellular CarcinomaLenvatinibTranscatheter Arterial Chemoembolization+1 more
Sun Yat-sen University32 enrolled1 locationNCT06740370
Recruiting
Phase 2

Ablative Radioembolization of Renal Cell Carcinoma Trial

Renal Cell Carcinoma (RCC)Radioembolization
Derek W. Cool16 enrolled1 locationNCT06642220
Recruiting
Phase 2

Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria

Hepatocellular Carcinoma (HCC)Radioembolization
Seoul National University Hospital100 enrolled4 locationsNCT06773845
Recruiting
Not Applicable

Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy

Primary AldosteronismSuprarenalectomySuper Selective Adrenal Artery Embolization
Xinjiang Medical University570 enrolled1 locationNCT06513585
Recruiting
Not Applicable

Efficacy of Angiographic Embolization vs Non-embolization of Moderate/Poor Vascularized Vertebral Metastases on Intraoperative Bleeding During Surgery Decompression and Vertebral Stabilization.

blood lossSpine MetastasisEarly Goal Directed Therapy+1 more
Istituto Ortopedico Rizzoli100 enrolled1 locationNCT03853434
Recruiting
Not Applicable

Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

Hepatocellular CarcinomaRadioembolization
Assistance Publique - Hôpitaux de Paris180 enrolled5 locationsNCT06334965
Recruiting

Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular CarcinomaSystemic TherapyTransarterial Chemoembolization
Sun Yat-sen University500 enrolled1 locationNCT06788353
Recruiting

The Combined Utility of Angio-CT and MRI in Managing Chronic Musculoskeletal Pain: a Prospective Study to Evaluate the Efficacy of Transarterial Microembolization

Magnetic Resonance ImagingComputed TomographyAngiography+2 more
Tri-Service General Hospital60 enrolled1 locationNCT06509087
Recruiting

Super Selective Adrenal Artery Embolization for Primary Aldosteronism: a Prospective Cohort Study(SAAE-PA)

Primary AldosteronismSuper Selective Adrenal Arterial Embolization
Xinjiang Medical University500 enrolled1 locationNCT06513676
Recruiting
Phase 2

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Intrahepatic CholangiocarcinomaApatinibTransarterial Chemoembolization+1 more
Sichuan Cancer Hospital and Research Institute20 enrolled1 locationNCT04834674